Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.
about
Pharmacological interventions for the acute management of hyperkalaemia in adultsRecent advances in treatment of heart failureLipids, blood pressure and kidney update 2015Clinical trials update from the European Society of Cardiology-Heart Failure meeting 2015: AUGMENT-HF, TITRATION, STOP-HF, HARMONIZE, LION HEART, MOOD-HF, and renin-angiotensin inhibitors in patients with heart and renal failureCharacterization of structure and function of ZS-9, a K+ selective ion trapUpdates in hyperkalemia: Outcomes and therapeutic strategies.Pharmacotherapy for comorbidities in chronic heart failure: a focus on hematinic deficiencies, diabetes mellitus and hyperkalemia.European Society of Cardiology congress update, Rome, 27-31 August 2016.The Diet and Haemodialysis Dyad: Three Eras, Four Open Questions and Four Paradoxes. A Narrative Review, Towards a Personalized, Patient-Centered Approach.Advances in treatment of hyperkalemia in chronic kidney disease.Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKDPotassium-Binding Agents for the Clinical Management of Hyperkalemia.Potassium and Its Discontents: New Insight, New TreatmentsNovel Bloodless Potassium Determination Using a Signal-Processed Single-Lead ECGMaintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial.Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review.Potential New Agents for the Management of Hyperkalemia.An update of the blockade of the renin angiotensin aldosterone system in clinical practice.How Dangerous Is Hyperkalemia?Treatment of Hyperkalemia in Heart Failure.Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy?New pharmacological approaches in heart failure therapy: developments and possibilities.The safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure.Pharmacodynamics and pharmacokinetics of sodium zirconium cyclosilicate [ZS-9] in the treatment of hyperkalemia.Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy.Potassium: friend or foe?New Agents in Treatment of Hyperkalemia: an Opportunity to Optimize Use of RAAS Inhibitors for Blood Pressure Control and Organ Protection in Patients with Chronic Kidney Disease.Calibrating the impact of dual RAAS blockade on the heart and the kidney - balancing risks and benefits.Pharmacologic Approaches to Electrolyte Abnormalities in Heart Failure.Sodium Zirconium Cyclosilicate (ZS-9): A Novel Agent for the Treatment of Hyperkalemia.Managing Hyperkalemia: Stepping Into a New Frontier.Physiology and pathophysiology of potassium homeostasis.Systematic Review and Meta-Analysis of Patiromer and Sodium Zirconium Cyclosilicate: A New Armamentarium for the Treatment of Hyperkalemia.Dialysate Composition for Hemodialysis: Changes and Changing Risk.Progress in the Presence of Failure: Updates in Chronic Systolic Heart Failure Management.Sodium zirconium cyclosilicate (ZS-9) for the treatment of hyperkalemia.Prevalence and Prognosis of Hyperkalemia in Patients with Acute Myocardial Infarction.Palatability and physical properties of potassium-binding resin RDX7675: comparison with sodium polystyrene sulfonateAssociation of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes.
P2860
Q24186355-45031BF4-4C32-48DC-AD52-3C4598DF384BQ26766223-2329F783-090D-4460-B1D7-475D58485875Q26771550-580C9539-D17C-4764-9E6C-0DAA2B4A7AA9Q26796378-99BE7626-E5CA-4FDD-BB99-78067DE04BD9Q28542799-EB539B70-78E2-4E6E-BFF4-2D7C75CEDF97Q30245585-8CC8882E-38D6-4CF9-817C-2BFA7B18A59FQ30250020-5430B686-61CE-45C5-8A88-EEB2431E19C0Q33615196-A5A8CFF2-EA9A-475C-8995-280774A6867FQ33616803-FE439059-D955-4F79-8485-C9801BC43D88Q34491934-C5A0194D-4B8D-458D-AD94-8E9CAAE86755Q36349441-AECD78A7-D4DB-4737-BEE1-01386E48AFF2Q36425315-2D5FA992-E9FF-40C7-BDF0-F8E845A31141Q36746113-B99812D7-4F94-4C49-A4D8-56746CE6A65BQ36877800-10B12047-DB92-4B2C-9DCA-F234DB21BE8FQ37275785-7AA2485D-F5D1-4180-9EEC-8A127005A367Q37722892-D521B1E2-D913-46BD-9C49-F27E65B25E61Q38544101-CD196D9E-611E-4819-A915-6EFF93F5F7D8Q38590227-79545354-CC83-4422-A3F0-5B3F7201C33EQ38639874-666202AA-5F2E-4DE7-A0F6-61A8C1C6E065Q38705827-1D9B12A3-90EC-4AB6-A184-B4D1F3B74E45Q38731482-D2A1B828-24B9-4A9F-8192-6E8A3885B8A5Q38734501-66503E08-A0C7-4893-9C12-2F9CD8E45397Q38759494-D69E0398-C311-47F4-AB10-6B4A4FF743B3Q38766590-40D77125-A872-448D-AE4D-76BF5D23AB23Q38783092-A803E77D-4BE6-459D-AE78-E8515FDF21FEQ38786625-3A2D72F4-22A0-496C-A50D-BD8CF8DB3D79Q38838019-7290CB7F-A59B-4A60-AEF6-BF0B0CB887B7Q38845433-6ED833F7-EBEC-49CB-BAAE-08BFFD377414Q38859432-0D495706-D6FA-4D5F-8C0B-D47F6088A72AQ38859478-3DCDD38C-13FA-4B1B-9D6F-51EDB7A42247Q38890685-80916FB3-7EAD-40A3-AF11-40842AEC1FF2Q38949822-131ECE81-2190-49E1-A7D6-4A46B97581E8Q38984717-853743DD-2416-44A3-A885-A0E856CABF2CQ38999653-4C7BFFD5-2FD5-4FD9-B2B4-98F91DB9EA7FQ39032556-961DC147-4B6A-4BF6-947A-ECB630D59EC8Q39317320-A5D8D1BE-E190-4098-A284-0E394683D78DQ40753618-6F7A2C1C-C373-4FC8-B4C6-FAAC7C67A539Q40810174-E910A6FF-E27D-4175-87C6-9BBF1923320AQ41355707-0208917D-A064-4212-BD6B-6BC213314AE3Q42375224-2D5022ED-6B24-4104-B9BD-47FE44A28F33
P2860
Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Effect of sodium zirconium cyc ...... IZE randomized clinical trial.
@ast
Effect of sodium zirconium cyc ...... IZE randomized clinical trial.
@en
Effect of sodium zirconium cyc ...... IZE randomized clinical trial.
@nl
type
label
Effect of sodium zirconium cyc ...... IZE randomized clinical trial.
@ast
Effect of sodium zirconium cyc ...... IZE randomized clinical trial.
@en
Effect of sodium zirconium cyc ...... IZE randomized clinical trial.
@nl
prefLabel
Effect of sodium zirconium cyc ...... IZE randomized clinical trial.
@ast
Effect of sodium zirconium cyc ...... IZE randomized clinical trial.
@en
Effect of sodium zirconium cyc ...... IZE randomized clinical trial.
@nl
P2093
P356
P1476
Effect of sodium zirconium cyc ...... NIZE randomized clinical trial
@en
P2093
Bhupinder Singh
Bruce Spinowitz
David Packham
Henrik S Rasmussen
Mikhail Kosiborod
Philip Lavin
Simon D Roger
Wajeh Y Qunibi
P304
P356
10.1001/JAMA.2014.15688
P407
P50
P577
2014-12-01T00:00:00Z